Skip to main content

Is Sunosi (solriamfetol) a controlled substance?

Medically reviewed by Drugs.com. Last updated on Sep 2, 2024.

Official answer

by Drugs.com

Yes. Sunosi (solriamfetol) is a Schedule IV Controlled Substance in the United States.

Sunosi (solriamfetol) is a selective dopamine and norepinephrine reuptake inhibitor (DNRI) for the treatment of excessive sleepiness in adult patients with narcolepsy or obstructive sleep apnea (OSA). It was approved by the FDA in March 2019.

Sunosi is a federally controlled substance (CIV) because it contains solriamfetol, which has the potential for abuse.

Sunosi should always be stored in a safe place to protect it from theft. Any unused or expired Sunosi should be disposed of via a medication take-back program, or mixed with an undesirable substance and thrown away in the household trash.

Read next

How do Ozempic, Mounjaro, Wegovy, Zepbound compare for weight loss?

Ozempic, Mounjaro, Wegovy and Zepbound can all lead to long-term weight loss, but only Wegovy and Zepbound are approved by the FDA for this use. In studies, Zepbound has led to a 21% weight loss in adults using the highest dose, while Wegovy has led to about a 15% weight loss. Continue reading

Why am I not losing weight on Mounjaro?

It takes time, about 8 to 12 weeks to see a 6% to 8% weight loss in adults using Mounjaro. Other reasons include the need to follow a reduced calorie diet and exercise program, your dose may need to be increased, or side effects may affect your treatment. Continue reading

Zepbound Vs Mounjaro: Complete Comparison Guide for Weight Loss and Diabetes Treatment

Comprehensive comparison of Zepbound vs Mounjaro. Learn about their uses, dosing, effectiveness, costs, and safety profiles to understand which medication might be right for you. Continue reading

Related medical questions

Drug information

Related support groups